Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (R/M HNSCC): A prospective phase II study

被引：0
|
作者：
Gui, L. [1 ]
Chen, X. [2 ]
He, X. [1 ]
Yang, J. [3 ]
Liu, P. [1 ]
Qin, Y. [1 ]
Shi, Y-K. [4 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Dept Med Oncol, Beijing, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Beijing Key Lab Clin Study Anticancer Mol Targete, Natl Clin Res Ctr Canc, Canc Hosp,Natl Canc Ctr,Dept Med Oncol, Beijing, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, CAMS PUMC, Dept Med Oncol, Beijing, Peoples R China
[4] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Med Oncol, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.468
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
360MO
引用
收藏
页码：S1609 / S1610
页数：2
相关论文
共 50 条
  • [1] Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A prospective, single-arm, open-label, phase 2 study
    Gui, Lin
    Chen, Xinrui
    Xie, Zucheng
    He, Xiaohui
    Yang, Jianliang
    Liu, Peng
    Qin, Yan
    Shi, Yuankai
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Pembrolizumab plus nabpaclitaxe and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma: A prospective phase II study
    Gui, L.
    He, X.
    Yang, J.
    Liu, P.
    Yan, Q.
    Shi, Y-K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S855 - S856
  • [3] Pembrolizumab plus nab-paclitaxel and platinum as firstline treatment in patients with with recurrent/ metastatic head and neck squamous-cell carcinoma (R/M SCC) of the nasal cavity and paranasal sinuses
    Gui, L.
    Shi, Y-K.
    Liu, P.
    Yang, J.
    He, X.
    ANNALS OF ONCOLOGY, 2023, 34 : S586 - S586
  • [4] Pembrolizumab plus anlotinib as first-line treatment in patients of CPS≥1 with recurrent or metastatic head and neck squamous-cell carcinoma: A prospective phase II study
    Gui, L.
    He, X.
    Yang, J.
    Liu, P.
    Qin, Y.
    Shi, Y-K.
    ANNALS OF ONCOLOGY, 2022, 33 : S1524 - S1524
  • [5] PembrolIzumab plus platinum and gemcitabine as first-line treatment of recurrent head and neck squamous cell carcinoma
    Ishak, W. Binti Wan
    Cheong, S.
    Nor, I. Muhamad
    Selvam, B.
    Ho, G.
    Tan, C.
    Wong, Y.
    Kue, P.
    Wai, A.
    Yahya, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S1386 - S1386
  • [6] KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)
    Burtness, B.
    Harrington, K. J.
    Greil, R.
    Soulieres, D.
    Tahara, M.
    De Castro, G., Jr.
    Psyrri, A.
    Rotllan, N. Baste
    Neupane, P. C.
    Bratland, A.
    Fuereder, T.
    Hughes, B. G. M.
    Mesia, R.
    Ngamphaiboon, N.
    Rordorf, T.
    Ishak, W. Z. Wan
    Roy, A.
    Cheng, J.
    Jin, F.
    Rischin, D.
    ANNALS OF ONCOLOGY, 2018, 29
  • [7] Efficacy, safety, and multi-omics analysis of pembrolizumab combined with nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: A single-arm phase 2 study
    Lin Gui
    Xinrui Chen
    Wen Zhang
    Zucheng Xie
    Yu Zhang
    Weihua Li
    Tongji Xie
    Jiarui Yao
    Haohua Zhu
    Le Tang
    Jianliang Yang
    Peng Liu
    Yan Qin
    Changgong Zhang
    Xiaohui He
    Yuankai Shi
    Chinese Journal of Cancer Research, 2024, 36 (06) : 713 - 747
  • [8] Efficacy, safety, and multi-omics analysis of pembrolizumab combined with nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: A single-arm phase 2 study
    Gui, Lin
    Chen, Xinrui
    Zhang, Wen
    Xie, Zucheng
    Zhang, Yu
    Li, Weihua
    Xie, Tongji
    Yao, Jiarui
    Zhu, Haohua
    Tang, Le
    Yang, Jianliang
    Liu, Peng
    Qin, Yan
    Zhang, Changgong
    He, Xiaohui
    Shi, Yuankai
    CHINESE JOURNAL OF CANCER RESEARCH, 2024, 36 (06)
  • [9] First-Line Pembrolizumab With or Without Lenvatinib in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Phase 3 LEAP-010 Study
    Harrington, Kevin
    Siu, Lillian L.
    Burtness, Barbara
    Cohen, Ezra
    Licitra, Lisa
    Rischin, Danny
    Zhu, Ying
    Okpara, Chinyere E.
    Pinheiro, Cecilia
    Swaby, Ramona F.
    Machiels, Jean-Pascal
    Tahara, Makoto
    ORAL ONCOLOGY, 2021, 118
  • [10] Phase III LEAP-010 study: first-line pembrolizumab with or without lenvatinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Siu, Lillian L.
    Burtness, Barbara
    Cohen, Ezra E. W.
    Harrington, Kevin Joseph
    Licitra, Lisa F.
    Rischin, Danny
    Zhu, Ying
    Lee, Chooi Peng
    Pinheiro, Cecilia
    Swaby, Ramona F.
    Machiels, Jean-Pascal H.
    Tahara, Makoto
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345